Authors
Priyanka Patra, Sreejesh Sreedharan, Anitha Ethirajan, Sumit Kumar Pramanik
Published in
Chemistry, an Asian journal. Volume 21. Issue 16. Pages e70885.
Abstract
Theranostic agents derived from aggregation-induced emission luminogens (AIEgens) offer significant potential, yet platforms that provide controlled drug release, organelle-specific action, and self-reporting capability are highly desired. Herein, we report a mitochondria-targeted prodrug system that integrates an AIE fluorophore with excited-state intramolecular proton transfer (ESIPT) characteristics, covalently linked to the anticancer drug dasatinib. The amphiphilic prodrug self-assembled into nanoparticles of around 210 nm with a spherical morphology. The probe is initially non-fluorescent due to ESIPT inhibition. Following cellular internalization, intracellular esterases cleave the carbonate linker, initiating two simultaneous processes: (1) the cytosolic release of dasatinib to inhibit proliferation-associated tyrosine kinases, and (2) the restoration of ESIPT and subsequent aggregation of the fluorophore, yielding a ratiometric fluorescence turn-on signal for real-time monitoring. The liberated probe, appended with a triphenylphosphine moiety, then selectively targets mitochondria, where it generates reactive oxygen species (ROS), inducing mitochondrial damage and promoting apoptosis. This combination of cytosolic kinase inhibition and mitochondria-targeted ROS production creates a powerful synergistic anticancer effect, demonstrating significantly enhanced efficacy over dasatinib alone. This multifunctional design pioneers a theranostic approach that merges precise drug activation, dynamic imaging, and organelle-specific therapy.
PMID:
42603861
Bibliographic data and abstract were imported from PubMed on 16 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0